Immix Biopharma terminates Richard Graydon; management sees no material impact

Immix Biopharma, Inc.

Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.
Management states Graydon's short tenure means no material effect on the business.
No replacement or further details on Graydon's role were disclosed in the filing.

item 8.01

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-033829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.